G enetic testing company Myriad Genetics, the defendant in a landmark Supreme Court case over gene patents, is back in the spotlight — this time, for withholding genetic data from patients ...

A month has gone by since the last earnings report for Myriad Genetics (MYGN). Shares have added about 23.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Genetic testing company Myriad Genetics (NASDAQ:MYGN) in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS ...

Myriad Genetics Ending Patent Dispute on Breast Cancer Risk Testing. The biotech company, the subject of a 2013 Supreme Court ruling that genes cannot be patented, said it was giving up trying to ...

Genetic tests like one offered by Myriad Genetics claim to analyze a patient's DNA and point them to the best depression drug for them. Myriad's test is called GeneSight and costs $2,000.

Myriad Genetics disparages its competitors for alleged mistakes in interpreting BRCA gene tests, but STAT found the company's claims were overstated.

A leading medical society is calling on Myriad Genetics Inc.MYGN9.42%increase; green up pointing triangle and other lab companies to share proprietary data from their genetic testing in a public ...